1. Home
  2. STOK vs CVEO Comparison

STOK vs CVEO Comparison

Compare STOK & CVEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • CVEO
  • Stock Information
  • Founded
  • STOK 2014
  • CVEO 1977
  • Country
  • STOK United States
  • CVEO United States
  • Employees
  • STOK N/A
  • CVEO N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • CVEO Hotels/Resorts
  • Sector
  • STOK Health Care
  • CVEO Consumer Discretionary
  • Exchange
  • STOK Nasdaq
  • CVEO Nasdaq
  • Market Cap
  • STOK 379.6M
  • CVEO 342.5M
  • IPO Year
  • STOK 2019
  • CVEO N/A
  • Fundamental
  • Price
  • STOK $7.69
  • CVEO $19.68
  • Analyst Decision
  • STOK Strong Buy
  • CVEO Strong Buy
  • Analyst Count
  • STOK 6
  • CVEO 1
  • Target Price
  • STOK $26.00
  • CVEO $28.00
  • AVG Volume (30 Days)
  • STOK 987.9K
  • CVEO 82.2K
  • Earning Date
  • STOK 05-05-2025
  • CVEO 04-29-2025
  • Dividend Yield
  • STOK N/A
  • CVEO 5.08%
  • EPS Growth
  • STOK N/A
  • CVEO N/A
  • EPS
  • STOK N/A
  • CVEO N/A
  • Revenue
  • STOK $36,555,000.00
  • CVEO $682,122,000.00
  • Revenue This Year
  • STOK $27.80
  • CVEO N/A
  • Revenue Next Year
  • STOK $9.53
  • CVEO $4.73
  • P/E Ratio
  • STOK N/A
  • CVEO N/A
  • Revenue Growth
  • STOK 316.34
  • CVEO N/A
  • 52 Week Low
  • STOK $5.35
  • CVEO $18.99
  • 52 Week High
  • STOK $17.58
  • CVEO $28.92
  • Technical
  • Relative Strength Index (RSI)
  • STOK 53.59
  • CVEO 40.04
  • Support Level
  • STOK $7.31
  • CVEO $19.19
  • Resistance Level
  • STOK $7.99
  • CVEO $20.44
  • Average True Range (ATR)
  • STOK 0.61
  • CVEO 1.05
  • MACD
  • STOK 0.23
  • CVEO -0.19
  • Stochastic Oscillator
  • STOK 88.64
  • CVEO 13.13

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

About CVEO Civeo Corporation (Canada)

Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia and the United States. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, Australia and the United States.

Share on Social Networks: